Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis

Thrombosis and Haemostasis

Volumn 79, Issue 5, 1998, Pages 897-901

  Charbonnier, Bernard A ^a   Fiessinger, Jean Noël ^b   Banga, J D ^c   Wenzel, Ernst ^d   D'Azemar, Pascal ^e   Sagnard, Luc ^e  

^a SERVICE DE DERMATOLOGIE   (France)

^b HÔPITAL BROUSSAIS   (France)

^c Academic Hospital   (Netherlands)

^d SAARLAND UNIVERSITY   (Germany)

^e SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; COUMARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; WARFARIN;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEMATOMA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHLEBOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031955043     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615089     Document Type: Article

References (16)

1. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low-molecular-weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309: 299-304.
2. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A metaanalysis. Arch Intern Med 1995; 155: 601-7.
3. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. The American Journal of Medicine 1996; 100: 269-77.
4. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 671-81.
5. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM., van der Meer J, Gallus AS, Simmoneau G, Chesterman CH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, d'Azémar P, Bueller HR. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-7.
6. Ninet J, Bachet P, Prandoni P, Ruol A, Vigo M, Barret A, Mericq O, Boneu B, Janvier G, Duroux P, Girard P, Laprevote-Heully MC, Sourou P, Robert D, Chagny M, Nenci G, Agnelli G, D'Addata M, Palumbo H, Bensaid J. A randomised trial of subcutaneous low-molecular-weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis - A collaborative European multicentre study. Thromb Haemost 1991; 65 (3): 251-6.
7. Théry C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, d'Azémar P, Coquart JP. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose ranging study. Circulation 1992; 85: 1380-9.
8. Lopaciuk S, Meissner A, Filipecki S, Zawilska K, Sowier J, Ciesielski L, Bielawiec M, Glowinski S, Czestochowska E. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68 (1): 14-8.
9. Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, Ten Cate JW. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. The Lancet 1992; 339: 441-5.
10. Mismetti P, Laporte-Simitsidis S, Boneu B, d'Azémar P, Gaud C, Duret JP, Decousus H. Pharmacodynamic study of a repeated once daily curative dosage of nadroparin (FRAXIPARINE®) in twelve elderly healthy volunteers. Haemostasis 1996; vol 2b (Suppl. 3), abstract no 93.
11. Blackweldeer WC. "Proving the null hypothesis" in clinical, controlled clinical trials. 1982; 3: 345-53.
12. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Bretteli HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
13. Brandjes DPM, Heijboer H, Büller HR, De Rijk M, Jagt H, Ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 21.
14. Lindmarker P, Holmström M, Granqvist S, Johnson H, Lockner D. Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72 (2): 186-90.
15. Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, Söderberg K. Once-daily subcutaneous Dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76 (2): 195-9.
16. Luomanmäki K, Grankvist S, Hallert C, Jauro I, Ketola K, Kim HC, Kiviniemi H, Koskivirta H, Sörskog L, Vilkko P. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine 1996; 240: 85-92.